MDWD vs. FOMX, CGC, MNMD, BTMD, ACB, CDXC, FTLF, BGXX, NAII, and MTEX
Should you be buying MediWound stock or one of its competitors? The main competitors of MediWound include Menlo Therapeutics (FOMX), Canopy Growth (CGC), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), FitLife Brands (FTLF), Bright Green (BGXX), Natural Alternatives International (NAII), and Mannatech (MTEX). These companies are all part of the "medical" sector.
Menlo Therapeutics (NASDAQ:FOMX) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.
Menlo Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.
46.5% of Menlo Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 3.0% of Menlo Therapeutics shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, MediWound had 4 more articles in the media than Menlo Therapeutics. MarketBeat recorded 4 mentions for MediWound and 0 mentions for Menlo Therapeutics. Menlo Therapeutics' average media sentiment score of 1.09 beat MediWound's score of 0.00 indicating that MediWound is being referred to more favorably in the news media.
MediWound has a consensus target price of $32.00, suggesting a potential upside of 87.79%. Given Menlo Therapeutics' higher possible upside, analysts clearly believe MediWound is more favorable than Menlo Therapeutics.
Menlo Therapeutics has a net margin of 0.00% compared to Menlo Therapeutics' net margin of -64.24%. Menlo Therapeutics' return on equity of -21.67% beat MediWound's return on equity.
MediWound has higher revenue and earnings than Menlo Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Menlo Therapeutics, indicating that it is currently the more affordable of the two stocks.
MediWound received 128 more outperform votes than Menlo Therapeutics when rated by MarketBeat users. However, 65.58% of users gave Menlo Therapeutics an outperform vote while only 62.24% of users gave MediWound an outperform vote.
Summary
MediWound beats Menlo Therapeutics on 12 of the 17 factors compared between the two stocks.
Get MediWound News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediWound Competitors List
Related Companies and Tools
